I'm an investor & start-up utility player (C*, VP, BD) with a PhD in Genetics, a Bachelors in physics, and a background in computer science. I fund & build companies that change the way science gets done with new tools and technologies.I currently work with a portfolio of early-stage life science start-ups on issues of fundraising, market
I'm an investor & start-up utility player (C*, VP, BD) with a PhD in Genetics, a Bachelors in physics, and a background in computer science. I fund & build companies that change the way science gets done with new tools and technologies.I currently work with a portfolio of early-stage life science start-ups on issues of fundraising, market & product strategy, and business development. I love working with teams of brilliant scientists and engineers to transition great ideas and technologies into great products and companies.
Keywords: genetics, DNA, synthetic biology, research tools, venture capital, capital formation, business development, strategy, life science technology.
Managing Director @ 5 Prime Ventures invests in early-stage life sciences technology companies with a focus on opportunities in research tools, molecular diagnostics, synthetic biology, and industrial biology. From 2012 to Present (3 years) San Francisco Bay AreaVenture Partner @ With over $1B under management, Fidelity Biosciences invests venture capital in private biopharmaceutical, medical technology, and healthcare IT and services companies. From October 2013 to Present (2 years 3 months) Board of Directors @ Cytek Biosciences stands for excellence and innovation in Flow Cytometry. Cytek's engineers, scientists and customer service representatives design, build and support flow cytometers. Cytek is the product of a merger between Cytek Development Inc, a respected leader in flow cytometry products and services, and Cytoville Inc, a venture capital-backed business in advanced medical instrument technology development. Cytek Biosciences is backed by Cowin Healthcare Fund, Easy Prosperity and Fidelity Biosciences.
http://www.cytekdev.com/ From June 2015 to Present (7 months) Board of Directors @ Caribou Biosciences is developing a platform to enable engineering of any genome, at any site, in any way. The Caribou technology platform centers around CRISPR-derived protein Cas9. Cas9 is a programmable nuclease that uses short RNA molecules, known as guide RNAs, to target the protein to a specific sequence within double-stranded DNA. By changing the sequence of the guide RNA, Cas9 can be re-directed to almost any DNA sequence. From 2014 to Present (1 year) Investor, Advisor @ Zephyrus Biosciences provides research tools to enable protein analysis at the single cell level.
www.zephyrusbio.com From 2014 to Present (1 year) Board Member @ From June 2009 to Present (6 years 7 months) Senior Program Officer, Global Health Discovery @ Shaped strategy and deployed capital in research and technology areas of central importance to the Foundation's Global Health mission, with a focus on emerging technologies such as genetically modified organisms and synthetic biology. Activities: Grants, BMGF Investment Committee member, Program-Related Investments (PRIs), Healthcare VC Roundtable leader. From October 2008 to May 2012 (3 years 8 months) Associate, Kauffman Fellow @ Fidelity Biosciences invests venture capital in private biopharmaceutical and medical technology companies. For more than 30 years, Fidelity Investments has been a significant presence in the venture capital and private equity industry, investing the firms own capital since 1969. During her Kauffman Fellowship at Fidelity Biosciences, Jenny focused on venture capital investment opportunities in diagnostics and life science tools. She served on the Boards of Directors of Accuri Cytometers and U.S. Genomics, and was the liaison with Fidelity's sister fund in India. From September 2006 to September 2008 (2 years 1 month) VP Corporate Development @ Secured a partnership to commercialize the company's biosensor technology in the Defense and Homeland Security markets. From September 2005 to September 2006 (1 year 1 month) VP Research & Development / CSO @ Oversaw the development and launch of the company's first molecular biology products, and drove seminal publications demonstrating applications of the company's technology. Managed high-caliber, multidisciplinary science and engineering team. From July 2004 to September 2005 (1 year 3 months) Director, Business Development / Director of Collaborative R&D @ Defined initial markets and products, and authored the VC-backed biotech's first business plan. Established and managed relationships with life science researchers in academia and industry, ensuring the early adoption of U.S. Genomics' single molecule detection technology. From September 2001 to July 2004 (2 years 11 months) Engagement Manager @ Advised leading pharmaceutical and biotech companies on business strategy. Led NY/Tri-state Summer Associate program (2000). From September 1998 to September 2001 (3 years 1 month)
Doctor of Philosophy (PhD), Genetics @ Yale University From 1992 to 1998 BS, Physics @ Georgia Institute of Technology From 1989 to 1992 Jenny Rooke is skilled in: Venture Capital, Biotechnology, Life Sciences, Genetics, Synthetic Biology, Strategic Planning, Business Strategy, Start-ups, Molecular Biology, Due Diligence, Capital Allocation, Research Tools, Global Health, Mission Related Investing, Program Related Investing
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension